Burden of Crohn’s disease in the United States: long-term healthcare and work-loss related costs

Abstract

Aims: To quantify the long-term direct and indirect costs among patients with Crohn's disease (CD) and specific subgroups of these patients in the United States from the private payer's perspective. Materials and methods: This retrospective study used the OptumHealth Care Solutions, Inc database (01 January 1999-31 March 2017) to match (1:5) adult patients with !2 claims for CD to patients without inflammatory bowel disease (IBD). Patterns observed during follow-up (i.e. biologics, opioids, or steroids; CD-related surgery; moderate-to-severe disease; and comorbidities) were used to identify CD subgroups. Comparisons of healthcare resource utilization, work loss days, and direct and indirect work loss-related costs were made between matched cohorts. Descriptive analyses of costs were conducted within each CD subgroup. Results: There were 6,715 and 33,575 patients in the CD and non-IBD cohorts, respectively. The direct burden was significantly higher in the CD cohort compared to the non-IBD cohort, with 0.34 inpatient admissions per patient per year (PPPY) versus 0.12 (217% increase; p < .

Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists

“…Absenteeism and presenteeism are common in patients with active IBD. 159,160 In pediatrics, discussion about the need for accommodations at school should be routinely asked and a plan provided as needed. For adults, physicians should 1 for screening tool to identify patients who may need 360-degree care services.…”

Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials

“…The economic burden of Crohn's disease is substantial 38 and may include costs associated with treating chronic comorbid conditions or complications, such as bowel obstruction, anaemia, colorectal cancer, fatigue and anxiety/depression, as well as costs associated with impaired work productivity. [38][39][40][41][42] Based on the reduction in overall work impairment after treatment with risankizumab compared with the withdrawal placebo group, and an average hourly wage of $31.03 in the United States in November 2021, 43 an estimated savings of $4841 to $6454 per patient per year could be achieved with risankizumab maintenance treatment. Similarly, in European countries, using an average hourly wage of €28.5 in 2020, 44 the estimated savings would be €4446 to €5928 per patient per year.…”

Worse outcomes and higher costs of care in fibrostenotic Crohn’s disease: a real-world propensity-matched analysis in the USA

“…34 Patients with CD who undergo CD-related surgeries bear more than twice the burden of cost than patients with moderate to severe CD (US$101 013 per patient per year (PPPY) vs US$44 934 PPPY, respectively). 35 Furthermore, recent studies have posited that anti-inflammatory therapies approved for CD are not effective in reducing the morbidity associated with intestinal fibrosis and stricture formation, as evidenced by increasing or plateaued rates of intestinal surgery in CD in recent decades. 3 8 12-15 Strengths of this study are that it represents the largest real-world analysis in FCD to date.…”